Back to All

Patient Mapping, designed to resolve commercialization challenges through deep analysis and actionable insights

15 September, 2021

Featured

DXRX – The Diagnostic Network® is the world’s first diagnostic commercialization platform for Precision Medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories. DXRX has been designed to resolve our clients’ commercial problems. Testing hurdles in the clinical diagnostic testing ecosystem continue to prevent the streamlined delivery of the right tests to the right patients at the right time, ultimately blocking patient access to life-saving Precision Medicine treatments. Currently there is a lack of up to date, detailed, real-world Precision Medicine diagnostics data which makes it difficult to make good data-informed decisions. The Patient Mapping tool aims to address the timeliness and granularity of real-world data for clients. 

Lab data is inherently challenging to analyze, due to the transactional nature of the data. Our data solutions provide actionable insight at each stage of the diagnostic commercialization process from biomarker discovery to in-market test availability.  

Built with our expertise, our proprietary “Deductive Diagnostic Pathways (DDPs®)” translate  millions of complex data points into valuable, actionable insights enabling immediate extraction of value against your specific business rules. We help our customers identify the best possible testing journey for patients at disease level enabling them to get the right medicines to the right patients, faster.  

DXRX Patient Mapping Solution is designed to enable longitudinal analysis of biomarker testing and the overall testing journey of individual patients to provide a deeper understanding of the commonalities, variances, and essential insights necessary to support decisions and drive successful commercialization of testing, thereby maximizing identification of patients eligible for a therapy. 

There are multiple benefits for clients using our Patient Mapping Solution. DXRX Patient Mapping Solution provides anytime access to our weekly data feed enabling you to make critical decisions in a time-sensitive manner as the market opportunity develops or flexes, enabling greater commercial outcomes. The tool is designed to deliver deep analysis built from our data repository of 493 labs, seven of which are the top ten reference labs in the US, and provides access to the most comprehensive data source in the US, delivering a true understanding of the current testing landscape and potential barriers. Clients will be able to understand the current testing journey by disease or stage in minutes to identify potential barriers and leakage points that need to be overcome to achieve maximum new diagnostic testing uptake rates.  

The tool also will allow clients to obtain details on both the ordering physician and the treating physician and identify the geographical areas where there are insufficiently tested patients, or the diagnostic market size of any given disease, as well as how and when that market is changing. Another important benefit is being able to access actual test results and turnaround times as well as standardized results indicating if a test result is positive or negative. Our better coverage across all lab types, accurate analysis by domain experts and more timely data makes it easier to determine what is the next best action for pharma clients. 

Learn more about our Patient Mapping Solution and request a short demo to discuss how we can tailor to your project here: DXRX Data Solutions: Patient Mapping (diaceutics.com)

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane
London
EC4V 5EQ.

Tel: +44 (0)20 3405 0205 or [email protected]


 
Caroline Forde
Robyn Fisher
 
Kieran Breheny